[go: up one dir, main page]

MXPA05008793A - Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. - Google Patents

Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.

Info

Publication number
MXPA05008793A
MXPA05008793A MXPA05008793A MXPA05008793A MXPA05008793A MX PA05008793 A MXPA05008793 A MX PA05008793A MX PA05008793 A MXPA05008793 A MX PA05008793A MX PA05008793 A MXPA05008793 A MX PA05008793A MX PA05008793 A MXPA05008793 A MX PA05008793A
Authority
MX
Mexico
Prior art keywords
methods
during treatment
prediction
polymorphism
suicidality during
Prior art date
Application number
MXPA05008793A
Other languages
English (en)
Inventor
Mihael Hristos Polymeropoulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05008793A publication Critical patent/MXPA05008793A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Esta invencion proporciona metodos para predecir la posibilidad de un comportamiento suicida o autodestructivo en un paciente durante el tratamiento. El metodo emplea la deteccion de un polimorfismo en el gen SLC6A3 en el Exon 9 A59G o un marcador sustituto, mediante diferentes metodos. Tambien se proporcionan metodos de tratamiento basados en la presencia o en la ausencia de este polimorfismo o marcador sustituto. Tambien se proporcionan estuches de diagnostico para utilizarse en los metodos de la invencion.
MXPA05008793A 2003-02-21 2004-02-20 Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. MXPA05008793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44901803P 2003-02-21 2003-02-21
PCT/EP2004/001692 WO2004074513A1 (en) 2003-02-21 2004-02-20 Methods for the prediction of suicidality during treatment

Publications (1)

Publication Number Publication Date
MXPA05008793A true MXPA05008793A (es) 2006-02-22

Family

ID=32908683

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008793A MXPA05008793A (es) 2003-02-21 2004-02-20 Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.

Country Status (9)

Country Link
US (1) US20070065821A1 (es)
EP (1) EP1597392A1 (es)
JP (1) JP2006518206A (es)
CN (1) CN1754000A (es)
AU (1) AU2004213582A1 (es)
CA (1) CA2516484A1 (es)
MX (1) MXPA05008793A (es)
PL (1) PL377601A1 (es)
WO (1) WO2004074513A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568729A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Biomarkers for the prediction of responsiveness to clozapine treatment
US8930178B2 (en) 2007-01-04 2015-01-06 Children's Hospital Medical Center Processing text with domain-specific spreading activation methods
WO2008136989A2 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting sod2-related disorders and uses thereof
WO2008144371A1 (en) * 2007-05-16 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosing suicidal tendencies
EP3522172B1 (en) 2009-04-27 2021-10-20 Children's Hospital Medical Center Method for assessing a neuropsychiatric condition of a human subject
WO2011119227A2 (en) * 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
WO2013040502A2 (en) * 2011-09-14 2013-03-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder
FR2993889B1 (fr) 2012-07-27 2014-08-22 Michelin & Cie Composition de caoutchouc thermo-expansible pour pneumatique
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
WO2014201515A1 (en) * 2013-06-18 2014-12-24 Deakin University Medical data processing for risk prediction
US10280464B2 (en) 2013-07-11 2019-05-07 The Johns Hopkins University DNA methylation and genotype specific biomarker of suicide attempt and/or suicide ideation
FR3009306B1 (fr) 2013-07-30 2015-07-31 Michelin & Cie Pneu dont la zone sommet est pourvue d’une couche interne reduisant les bruits de roulage
FR3009305A1 (fr) 2013-07-30 2015-02-06 Michelin & Cie Composition de caoutchouc thermo-expansible et pneumatique comportant une telle composition
CA2891830A1 (en) * 2015-05-15 2016-11-15 Centre For Addiction And Mental Health Genetic markers for suicide risk and related methods

Also Published As

Publication number Publication date
CN1754000A (zh) 2006-03-29
JP2006518206A (ja) 2006-08-10
PL377601A1 (pl) 2006-02-06
US20070065821A1 (en) 2007-03-22
AU2004213582A1 (en) 2004-09-02
EP1597392A1 (en) 2005-11-23
CA2516484A1 (en) 2004-09-02
WO2004074513A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
EP2021534A4 (en) ESTIMATE AND REDUCE THE RISK OF GRAFT VERSUS HOST REACTION
PT1597391E (pt) Utilização de arn intrónico para medir a expressão genética
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
ATE424560T1 (de) Marker für neuromyelitis optica
MX2008011185A (es) Marcadores para adiccion.
WO2005048818A3 (en) Methods of diagnosing renal disease
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
DE60328198D1 (de) Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
ATE277353T1 (de) Tau als marker für frühe schäden des zentralen nervensystems
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
AU2003233292A8 (en) Protein c polymorphisms
DE602004021366D1 (es)
TW200500065A (en) Antiarthritic combinations
BRPI0407447A (pt) Métodos para a previsão de suicidabilidade durante o tratamento
DE602004030107D1 (de) Suszeptibilitätsgen für die alzheimersche krankheit
DE602007010939D1 (de) Abcbi-genotypisierung zur vorhersage der mikrotubuli-stabilisatorwirkstoffinduzierten toxizität
ATE498021T1 (de) Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität
DE602004014135D1 (de) Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität

Legal Events

Date Code Title Description
FA Abandonment or withdrawal